VSTM2L

Across TCGA pan-cancer cohorts, VSTM2L mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated VSTM2L data layer compared with 26 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher VSTM2L mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated VSTM2L expression acts as an unfavorable survival marker.

LUAD, LSCC, and PDAC are the cancer types where VSTM2L mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Quartile	All	0.600	0.890	.010	9	view →
LSCC	OS	Median	II,III,IV	0.717	0.981	.033	3	view →
PDAC	DFS	Median	IV	0.245	0.741	.038	3	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

VSTM2L–LUAD (OS)

Open the LUAD breakdown →